Top Picks: Accredited Activities

EHA 2017 Congress Highlights in Acute Myeloid Leukemia

Ehab Atallah, MD; Jorge E. Cortes, MD; Naval Daver, MD; Keith W. Pratz, MD; Eytan M. Stein, MD; Richard M. Stone, MD

Exploring Epigenetics in AML Oncogenesis

Farhad Ravandi-Kashani, MD

  • VIDEO: Practice Essential - Emerging Agents Impacting Future Treatment Strategies in AML - Pinkal Desai, MD, MPH
  • VIDEO: FAQ - What are the latest updates on the IDH1 and IDH2 inhibitor studies? - Naval Daver, MD
  • VIDEO: FAQ - What are the latest updates on the Beat AML Master Trial? - Brian Druker, MD
  • VIDEO: FAQ - What FLT3 inhibitors are being evaluated in AML and what is the status of development of these agents? - Naval Daver, MD
  • VIDEO: FAQ - In the area of prognostic markers in AML, what do community providers need to know to be up-to-date? - Brian Druker, MD
  • VIDEO: FAQ - What are the most exciting new agents in AML and where are they in clinical development? - Naval Daver, MD
  • VIDEO: FAQ - Is there data to support routine use of FLT3 inhibitors in AML patients outside of a clinical trial? - Naval Daver, MD
  • Clinical Trials Tracker e-Newsletter - Immunotherapy in AML: Monoclonal Antibodies - Naval Daver, MD and Elizabeth Paczolt, MD, FACNM

Supporters

MediCom Worldwide, Inc. would like to recognize and thank the following companies for their educational support of Managing AML.com

  • Agios Pharmaceuticals, Inc.
  • Celgene Corporation
  • Helsinn
  • Incyte Corporation
  • Jazz Pharmaceuticals, Inc.
  • Novartis Pharmaceuticals

MediCom Oncology Links

Please visit these other members of the MediCom Oncology family of sites.

Managing MDS Managing Myeloma The Practical Oncologist
Managing Hodgkin Lymphoma Partners in Pancreatic Cancer Emerging Solutions in Pain